- Facility will manufacture pharmaceutical products, including innovative antibody drugs
- 600 construction jobs and 100 highly specialised roles in engineering, science, and technology created in the area during construction phase and when fully operational
DUBLIN, 25 March, 2024 – Today, Astellas Ireland Co., Ltd, a wholly owned subsidiary of Astellas Pharma Inc., held a ceremony to mark the breaking of the ground and start of construction for its new €330 million, state-of-the-art facility at Kerry Technology Park, Tralee, Co. Kerry. The ceremony, held at the site and Munster Technological University, was attended by Minister for Enterprise, Trade and Employment, Simon Coveney, Minister for Education, Norma Foley TD, IDA* CEO Michael Lohan, representatives of Kerry County Council, project partners and senior Astellas executives.
The new facility, which has been designed with sustainability at its core, will accelerate the expansion of Astellas’ in-house production capabilities and ensure a stable supply of high quality medicines to patients around the world. The project is set to create significant employment opportunities in the area, including 600 construction jobs and 100 highly specialised roles in engineering, science, and technology. The facility is planned to be operational by 2028.
Minister for Enterprise Trade & Employment, Simon Coveney TD, said: “As our Enterprise Policy has a key regional dimension, once again, I wish to celebrate the company’s decision to build its new cutting-edge facility in Tralee which represents a major note of confidence in the southwest region. Astellas’ commitment to a facility that will incorporate the highest national and international best practice in energy and environmental design is also aligned with the quality of development that my department and the IDA are looking to deliver for our citizens, fully in keeping with the Government’s commitment to a decarbonised economy and society.”
Minister for Education and Kerry TD, Norma Foley, said: “I am very pleased to see the further development of Astellas, which represents the single biggest investment in Tralee town and the county as a whole for many years. This is a phenomenal vote of confidence by Astellas in Kerry. It is, in many respects, a game changer for the entire southwest region. I am delighted that we are now marking the ‘groundbreaking’ stage of this exciting development. I wish to thank Astellas for its vision, ambition and confidence in Tralee and County Kerry and I look forward to the project developing at pace.”
Hideki Shima, Chief Manufacturing Officer, Astellas Pharma, said: “Today marks a significant achievement for our company and reflects our continued commitment to expansion and innovation in the region. Not only will it further the Astellas vision to be at the forefront of healthcare change by turning innovative science into value for patients, but it will also be a growth opportunity for the many people who will bring this facility to life. Together we hope to build something best in class, producing quality products that people need, and striving to continue putting patients first.”
Louis Collins, Executive Director, Kerry Operations, Astellas Pharma Ireland Ltd, said: “This is an incredibly exciting day for Astellas, and all those who have helped make this vision a reality. We have been grateful for the time and professionalism of the local authorities and the engagement from the local community throughout this process. We also want to thank our project and design partners and the Astellas team across Ireland and globally. I have no doubt that it is this partnership and support that has been key getting us to where we are today, for which we are incredibly grateful.”
CEO of the IDA, Michael Lohan, said: “Astellas’ decision last year to expand its operations in Ireland was warmly welcomed, especially here in Kerry where the company has had an operation since 1990. Today’s sod-turning is symbolic as it heralds a new chapter for this global pharmaceutical leader in Ireland and is testament to the company’s leadership and commitment to innovation, sustainability and to the Southwest Region. I wish to congratulate Astellas on today’s ground-breaking and assure the team of IDA Ireland’s continued partnership and support.”
On an environmental level, the building will fall in line with Astellas’ ambitious sustainability values and targets, incorporating the highest national and international best practice in energy and environmental design. As a result, this project aims to cut water use by approximately half, reduce operational energy intensity by more than one-third, and produce zero waste to landfill (compared with LEED® baseline). These measures along with onsite renewable technology including solar PV panels and biomass boiler underpin Astellas’ efforts in the mitigation of climate change.
Astellas recently announced further investment in Kerry, taking over the lease of the Advanced Technology Building, also at Kerry Technology Park.
___ENDS___
Outline of the new state-of-the-art facility in Tralee
- Site area approximately 44.7 acres.
- 3-story building, total floor area of 17,000 square metres. Building footprint approximately 7,300
square metres
Concept image of new facility
*Industrial Development Authority’s (IDA):
IDA Ireland is the official agency responsible for the attraction and retention of inward foreign direct investment into Ireland.
About Astellas Ireland Co Ltd
Astellas has had a presence in Ireland for more than 35 years and now employs over 500 people across three locations. Astellas Pharma Co., Ltd (APCL) is located in Mulhuddart, Dublin, and is responsible for the sale and marketing of medicinal products in Ireland. Astellas Ireland Co., Ltd (AICL) is responsible for two manufacturing sites located in Killorglin, Co. Kerry and Mulhuddart, Co. Dublin. The new facility will be in Tralee, Co. Kerry.
Astellas operations in Ireland have a significant local impact and global reach. Our existing manufacturing sites in Ireland supply products to 120 countries worldwide.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
###
Contact for enquiries or additional information:
Astellas Pharma Europe.
Corporate Communications
[email protected]
MAT-GB-NON-2024-00210 April 2024
The Astellas EST-C Communications team
will respond to emails from journalists.
For general media enquiries,
please email [email protected].